Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thyroid Neoplasms × Docetaxel × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 15 Squamous Cell Carcinoma of Head and Neck 7 Prostatic Neoplasms 7 Lung Neoplasms 6 Breast Neoplasms 6 Urinary Bladder Neoplasms 5 Prostatic Neoplasms, Castration-Resistant 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Carcinoma, Transitional Cell 4 Stomach Neoplasms 3 Ovarian Neoplasms 3 Neoplasms 3 Laryngeal Neoplasms 3 Triple Negative Breast Neoplasms 2 Salivary Gland Neoplasms 2 Oropharyngeal Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 2 Neoplasm Metastasis 2 Mouth Neoplasms 2 Lymphoid Interstitial Pneumonia 2 Fallopian Tube Neoplasms 2 Endometrial Neoplasms 2 Adenocarcinoma Of Esophagus 2 Vaccinia 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Tongue Neoplasms 1 Thyroid Neoplasms 1 Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 1 Solid Tumor, Adult 1

Interventions

lenvatinib 3 trametinib 2 pembrolizumab 2 anlotinib 2 Specimen Handling 2 Nivolumab 2 Magnetic Resonance Spectroscopy 2 Cyclophosphamide 2 Biopsy 2 tremelimumab 1 trastuzumab deruxtecan 1 selpercatinib 1 pralsetinib 1 naporafenib 1 gallium Ga 68 dotatate 1 fludarabine phosphate 1 durvalumab 1 defactinib 1 dabrafenib 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Sorafenib 1 Radiotherapy 1 Neck Dissection 1 Molecular Diagnostic Techniques 1 Ipilimumab 1 Interleukin-13 1 Fluorodeoxyglucose F18 1 Eye Movement Desensitization Reprocessing 1 Etoposide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03360890 2026-03-13

iPRIME

University of Chicago

Phase 2 Active not recruiting

Salivary Gland Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡